Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5844958 | 1.00 | LMNA (0.46) | LMNASMN1; SMN2L3MBTL1ADRA1DADRA1A | |
| SCHEMBL4961334 | 0.92 | LMNA (0.44) | LMNASMN1; SMN2L3MBTL1ADRA1DADRA1A | |
| SCHEMBL7781954 | 0.91 | CA2 (0.53) | LMNASMN1; SMN2L3MBTL1CA2MAPK1 | |
| SCHEMBL4961837 | 0.91 | LMNA (0.41) | LMNASMN1; SMN2L3MBTL1ADRA1DADRA1A | |
| SCHEMBL7782073 | 0.91 | LMNA (0.48) | LMNASMN1; SMN2L3MBTL1CA2MAPK1 | |
| SCHEMBL6976439 | 0.91 | LMNA (0.48) | LMNASMN1; SMN2L3MBTL1CA2MAPK1 | |
| SCHEMBL6976444 | 0.91 | LMNA (0.48) | LMNASMN1; SMN2L3MBTL1CA2MAPK1 | |
| SCHEMBL15865343 | 0.88 | L3MBTL1 (0.44) | LMNAL3MBTL1ADRA1DADRA1AADRA1B | |
| SCHEMBL15865344 | 0.88 | L3MBTL1 (0.44) | LMNAL3MBTL1ADRA1DADRA1AADRA1B | |
| SCHEMBL4961003 | 0.87 | LMNA (0.46) | LMNASMN1; SMN2L3MBTL1ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271634-B1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | INTEGRATIVE RES LAB SWEDEN AB (SE) | 2014-02-12 | — | — | EP | disclosed |
| US-8524766-B2 | Modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2013-09-03 | — | — | US | disclosed |
| US-20110105461-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-05-05 | — | — | US | disclosed |
| EP-2271634-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009133107-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2009-11-05 | — | — | WO | disclosed |
| US-7041683-B2 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1, 4-benzodiozan | WYETH (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1381600-A1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-BENZODIOXAN | Wyeth, A Corporation of the State of Delaware (US) | 2004-01-21 | — | — | EP | disclosed |
| US-20030236241-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan | WYETH | 2003-12-25 | — | — | US | disclosed |
| EP-0839145-B1 | HETEROCYCLYLCARBOXAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2003-11-05 | — | — | EP | disclosed |
| US-6559169-B2 | For therapy of depression, anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder attention deficit disorder,obsessive compulsive disorder, obesity, eating disorders, sexual dysfunction | WYETH | 2003-05-06 | — | — | US | disclosed |
| US-20020193400-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan | WYETH (US) | 2002-12-19 | — | — | US | disclosed |
| WO-2002085896-A1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-BENZODIOXAN | WYETH (US) | 2002-10-31 | — | — | WO | disclosed |
| US-5935973-A | AFFINITY FOR 5-HT1A, ALPHA1, ALPHA2 AND/OR D2 RECEPTORS; ANTIDEPRESSANTS, ANXIOLYTIC AGENTS, PSYCHOSES, DYSKINESIAS, PARKINSON'S DISEASE, HYPOTENSIVE AGENTS, TOURETTE'S SYNDROME, OBSESSIVE-COMPULSIVE BEHAVIOUR, PANIC ATTACKS, SOCIAL PHOBIAS | KNOLL AKTIENGESELLSCHAFT (DE) | 1999-08-10 | — | — | US | disclosed |
| EP-0839145-A1 | HETEROCYCLYLCARBOXAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | Knoll AG (DE) | 1998-05-06 | — | — | EP | disclosed |
| WO-1997003071-A1 | HETEROCYCLYLCARBOXAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | KNOLL AKTIENGESELLSCHAFT (DE) | 1997-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193400-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan | OPRD1, DRD1, DRD2 | LMNA 3241/4885SMN1; SMN2 2556/4885L3MBTL1 3569/4885 |
| US-20030236241-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan | OPRD1, DRD1, DRD2 | LMNA 3241/4885SMN1; SMN2 2556/4885L3MBTL1 3569/4885 |
| US-20110105461-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | DBH, SLC18A2, SLC6A3 | LMNA 4504/4885SMN1; SMN2 689/4885L3MBTL1 4244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.